Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Mario Sznol
Yale University, Department: Dermatology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Bristol Meyers Squibb, Inc.
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Dr. Sznol received fees in the range of (b)(4) from Bristol Meyers Squibb Inc. for consulting on clinical development of immunotherapies in general, and for development of both anti-PD 1 and ipilimumab. The studies in Project 2 of the above referenced award could have a direct impact for current development of anti-PD 1 and Ipilimumab as a novel and promising approach for melanoma therapy. A Bristol Meyers Squibb compound will be tested directly in the specific aims of Project 2 (BMS-936558) in both pre clinical models of Melanoma, as well as assessing the association between B7-H1/PD-1 expression in human melanoma microenvironments with clinical response to anti-PD-1 therapy. Based on the aims of the study, Dr. Sznol’s role on the project, and his related consulting activities with Bristol Meyers Squibb Inc., Yale University determined that a Financial Conflict of Interest exists with Dr. Sznol’s role as Co-leader of Project 2 on the above award.
Yale SPORE in Skin Cancer
The studies will address major questions in melanoma: 1) Can cumulative carcinogenic sunlight exposure can be measured as DNA damage and mutations in individual's skin? 2) Can melanomas be classified based on mutations in specific networks? 3) Are there molecular markers that can predict a patient's response to targeted and immunotherapies? 4) Is the newly discovered 'RAC1 pathway' can become an alternative therapeutic target?
Filed on October 19, 2012.
Tell us what you know about Mario Sznol's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.